Entera Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered macromolecule therapeutics for use in areas with unmet medical need. Co.'s main focus is applying its technology to develop an oral formulation of human parathyroid hormone (1-34) (PTH), which has been approved in the U.S. in injectable form. Co.'s primary oral PTH product candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. The ENTX stock yearly return is shown above.
The yearly return on the ENTX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ENTX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|